Overview

ImPACT

Product Combination Indication Preclinical Manufacturing Phase 1 Phase 2

HS-410
(Vesigenurtacel-L)

monotherapy; BCG

NMIBC

Pre-Clinical Phase completed
Manufacturing Phase completed
Phase 1 completed
Phase 2 in progress

HS-110
(Viagenpumatucel-L)

nivolumab and other checkpoint inhibitors

NSCLC

Pre-Clinical Phase completed
Manufacturing Phase completed
Phase 1 completed
Phase 2 in progress

HS-110
(Viagenpumatucel-L)

cyclophosphamide

NSCLC

Pre-Clinical Phase completed
Manufacturing Phase completed
Phase 1 completed
Phase 2 in progress